Micheli Francesco Form 5

February 14	, 2013										
FORM								OMB AF	PROVAL		
. •		STATES SEC	S SECURITIES AND EXCHANGE COMMISSION				IMISSION	OMB Number:	3235-0362		
Check thi		V	Washington, D.C. 20549 CATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES					Expires:	January 31,		
to Section Form 4 or 5 obligati may conti	n 16. r Form ANN ions inue.							Estimated average burden hours per response 1.0			
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Form 3 Holdings Section 17(a) of the Public Utility Holding Company Act of 1935 or Section Reported Form 4 30(h) of the Investment Company Act of 1940 Transactions Reported											
1. Name and A Micheli Fra	Address of Reporting ancesco	Symb INTI	2. Issuer Name and Ticker or Trading Symbol INTERCEPT PHARMACEUTICALS INC [ICPT]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle)			3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2012				Director X 10% Owner Officer (give title Other (specify below)				
C/O GENE DE GRASS	XTRA S.P.A., ' SI, 11		172012								
	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Reporting (check applicable line)				
MILAN,Â	L6Â 20124							One Reporting Person More than One Reporting			
(City)	(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, any (Month/Day/Yea	Code	4. Securities Acquired or Disposed of (D) (Instr. 3, 4 and 5)		red (A)	5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year	Ownership Form:	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Amount	(A) or (D)	Price	(Instr. 3 and 4)	(Instr. 4)			
Common Stock, par value \$0.001 per share	Â	Â	3(1)	Â	Â	Â	Â	I	See footnote (4)		
Common Stock, par value	10/16/2012	(5)	C4	2,403,837	A	\$ (2) (3)	8,052,598	I	See footnote (4)		

Edgar Filing: Micheli Francesco - Form 5

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.		Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.						SEC 2270 (9-02)	
Common Stock, par value \$0.001 per share	10/16/2012	(5)	C4	778,843	A	\$ (2) (3)	8,052,598	I	See footnote (4)
Common Stock, par value \$0.001 per share	10/16/2012	(5)	C4	2,403,837	A	\$ <u>(2)</u> <u>(3)</u>	8,052,598	I	See footnote (4)
\$0.001 per share									

 $\label{thm:convergence} \begin{tabular}{ll} Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned \\ (\emph{e.g.}, puts, calls, warrants, options, convertible securities) \\ \end{tabular}$

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amo Underlying Secu (Instr. 3 and 4)	
					(A)	(D)	Date Exercisable	Expiration Date	Title	Ar Nu Sh
Series A Preferred Stock	Â	Â	Â	3(7)	Â	Â	(11)	(11)	Common Stock	
Series B Preferred Stock	Â	Â	Â	3(8)	Â	Â	(11)	(11)	Common Stock	
Series C Preferred Stock	Â	Â	Â	3(9)	Â	Â	(11)	(11)	Common Stock	
Warrant to Purchase Common Stock	\$ 10.41	Â	Â	3(10)	Â	Â	(12)	01/20/2015	Common Stock	
Series A Preferred Stock	Â	10/16/2012	(5)	C4	1	13,888,889	(2)(3)	(2)(3)	Common Stock	2,
Series B Preferred	Â	10/16/2012	(5)	C4	1	13,888,889	(2)(3)	(2)(3)	Common Stock	2,

Stock

Series C

Preferred \hat{A} 10/16/2012 \hat{A} (5) C4 \hat{A} 4,500,000 \hat{A} (2)(3) \hat{A} (2)(3) Common Stock

Stock

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Micheli Francesco C/O GENEXTRA S.P.A. VIA G. DE GRASSI, 11 MILAN. L6Â 20124

 \hat{A} \hat{A} \hat{A} \hat{A} \hat{A}

Signatures

/s/ Allison Sherrier, attorney-in-fact for Mr. Francesco Micheli

02/14/2013

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Genextra. S.p.A. owned 1,600,700 shares of Common Stock on October 10, 2012, the date on which the reporting person became a greater than 10% owner of the Issuer.
 - Immediately prior the completion of the Issuer's initial public offering (the "IPO"), Genextra S.p.A. beneficially owned 13,888,889 shares of the Issuer's Series B Preferred Stock and 4,500,000 shares of the Issuer's Series B Preferred Stock and 4,500,000 shares of the Issuer's Series B Preferred Stock and 4,500,000 shares of the
- (2) Issuer's Series C Preferred Stock. The Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date, and were converted into the Issuer's common stock, without the payment of additional consideration, upon the closing of the Issuer's IPO based on the conversion rate then in effect, as determined in accordance with the Issuer's Restated Certificate of Incorporation, as amended.
- Upon the closing of the IPO, all 13,888,889 shares of Series A Preferred Stock, 13,888,889 shares of Series B Preferred Stock and
 4,500,000 shares of Series C Preferred Stock held by Genextra S.p.A. were converted into 2,403,837 shares of common stock, 2,403,837 shares of common stock and 778,843 shares of common stock, respectively (or a conversion rate of 1-for-5.7778), and such conversion is reflected in the amount of common stock underlying the securities.
- Held by Genextra S.p.A. Mr. Micheli is an Executive Director of Genextra S.p.A. and, in such capacity, Mr. Micheli exercises voting control over the shares of common stock owned by Genextra S.p.A. Mr. Micheli disclaims beneficial ownership with respect to any such shares, except to the extent of his pecuniary interest therein, if any.
- (5) Not applicable.
- The shares of preferred stock would convert into common stock upon the closing of the Issuer's initial public offering using a calculation set forth in the Issuer's Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The preferred stock would convert on a 1-for-5.7778 basis and such conversion is reflected in the amount of common stock
- conversion. The preferred stock would convert on a 1-for-5.7778 basis and such conversion is reflected in the amount of common stock underlying the security
- (7) Genextra. S.p.A. owned 2,403,837 shares of Series A Preferred Stock on October 10, 2012, the date on which the reporting person became a greater than 10% owner of the Issuer.
- (8) Genextra. S.p.A. owned 2,403,837 shares of Series B Preferred Stock on October 10, 2012, the date on which the reporting person became a greater than 10% owner of the Issuer.
- (9) Genextra. S.p.A. owned 778,843 shares of Series C Preferred Stock on October 10, 2012, the date on which the reporting person became a greater than 10% owner of the Issuer.

Reporting Owners 3

Edgar Filing: Micheli Francesco - Form 5

- (10) Genextra. S.p.A. owned warrants to purchase 865,381 shares of Common Stock on October 10, 2012, the date on which the reporting person became a greater than 10% owner of the Issuer.
- (11) These shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, at any time after the issuance of such shares, at the holder's election.
- (12) This Warrant is immediately exercisable.

Â

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.